We report that homeodomain-only protein (HOP) is expressed in the suprabasal layer of normal upper aerodigestive tract epithelium and expression strongly decreases in hypopharyngeal carcinoma. Interestingly, HOP has very recently been shown to be a tumour suppressor involved in differentiation, suggesting that HOP may have a similar role in head and neck squamous cell carcinoma (HNSSC).
Head and neck squamous cell carcinoma (HNSCC) occurs through malignant conversion of basal layer epithelial cells of the upper aerodigestive tract (pharynx, hypopharynx and larynx) and the oral cavity. HNSSC is the fifth most common cancer worldwide (Sankaranarayanan et al, 1998 ) and the 5-year survival rate is only 18% for hypopharyngeal carcinoma (Dimery and Hong, 1993) . We have performed differential display (DD) (Lemaire et al, 2003) and DNA microarray (Cromer et al, 2004) analysis of hypopharyngeal tumours to search for new biomarkers and targets for drug design. In this complementary study, we report that expression of homeodomain-only protein (HOP) is strongly decreased in tumours. Interestingly, in a series of recent independent reports, this protein under different names (mOB1/HOP/LAGY/NECC1/ SMAP31) has been shown to be involved in development (Adu et al, 2002; Chen et al, 2002; Shin et al, 2002; Asanoma et al, 2003; Chen et al, 2003) and has been shown to be a potent tumour suppressor (Asanoma et al, 2003) . We show here that HOP is expressed at a precise stage of epidermoid cell differentiation and its expression is lost in HNSSC, suggesting that HOP may be a general tumour suppressor gene involved in keratinocyte differentiation.
MATERIALS AND METHODS
Tumour samples, Northerns, Virtual Northerns and real-time quantitative PCR (RT -QPCR) were as described previously (Lemaire et al, 2003) . Virtual signifies the use in the Northern blots of SMART cDNA synthesised by SMART (Clontech, http:// www.bdbiosciences.com/clontech/). The primer sequences were HOP, 5 0 -TCAACAAGGTCGACAAGCAC-3 0 and 5 0 -TCTGTGACG-GATCTGCACTC-3 0 ; the ubiquitous gene RPLPO, 5 0 -GAAGGCTGTGGTGCTGATGG-3 0 and 5 0 -CCGGATATGAGGCAG-CAGTT -3 0 . For each PCR, the unknown sample expression level was estimated relative to standard curves using a pool of normal samples. PCR reactions were run at least twice for each sample and results normalised using RPLP0 as an internal control. In situ hybridisation (ISH) was performed by a standard technique (Strahle et al, 1994; Cau et al, 1997) . Nonradioactive digoxigenine-labelled RNA probes were synthesised from 15 mg of linearised F1.4-pGEMT-Easy (antisense: Aat2 and SP6 RNA polymerase; sense: Spe1 and T7 polymerase). F1.4-pGEMT-Easy: pGEM-T Easy with a 572 bp insert corresponding to SMAP31 (now HOP transcript variant 1, accession number BC014225, nt 675 -1246).
RESULTS
We isolated a differentially expressed sequence (F1. 4) in a DD analysis of RNA from HNSCC and matching normal tissue. The sequence corresponded to SMAP31/LAGY, which at that time was annotated in the NCBI database as a clone underexpressed in choriocarcinoma vs normal placenta villi (SMAP31) and lung cancer vs normal lung (LAGY). More recently, it has been called HOP (Chen et al, 2002; Shin et al, 2002) since it is a homeodomainonly protein. Homeodomain-only protein was not detected in our previous study (Lemaire et al, 2003) , apparently because it is not efficiently labelled with the primer mixtures that we used to make focused probes for Reverse Northern analysis. However, in further studies using Virtual Northerns (Northerns with SMART amplified cDNAs), we found a striking decrease in expression in tumours in nine matched tumour-normal pairs ( Figure 1A ). The major transcript migrates around 1000 bp, which corresponds to the sizes reported for HOP (1200 bp, (Chen et al, 2002; Shin et al, 2002) ), LAGY (HOP/LAGY transcript variants: 1013 bp, NM_139212; 989 bp, NM_139211, 1265 bp, NM_032495 (Chen et al, 2003) ), and NECC1/SMAP31-22, SMAP31-R and SMAP31-12 (980 bp, AB059409, 989 bp, AB059410 and 1097 bp, AB059408, respectively, (Asanoma et al, 2003) ]).
HOP expression was analysed in other patients by Northern ( Figure 1B ) and slot (data not shown) blotting. As expected, the predominant band on Northerns migrates around 1000 bp (compared to the ribosomal RNA markers, Figure 1B ). HOP expression was found to be decreased in 18 out of 19 tumours compared to normal samples. Expression of HOP was also decreased in involved lymph nodes (L; Figure 1B , patients 11, 13, 14). The expression levels of HOP were assessed by RT-QPCR in a panel of 33 hypopharyngeal carcinomas, for which there were 23 matched normal tissues (Figure 2 ). HOP was expressed at high levels in normal samples (21 out of 23) and strikingly decreased in all tumour samples (average fold change ¼ 27). In situ hybridisation (ISH) of frozen sections was used to localise HOP mRNA expression (Figure 3 ). HOP expression was detected in the suprabasal layer of the epithelium of normal tissue (uvula) (3A, antisense; 3B, haematoxylin/eosin). There was no significant signal with the sense probe and normal tissue, or with the antisense probe and several tumour samples (data not shown). The expression pattern is compatible with a role for HOP in epithelial differentiation and suggested that HOP expression might be associated with the degree of differentiation of the tumours. Homeodomain-only protein expression, measured by RT-QPCR, indicates that there is no statistically significant difference according to the histopathological differentiation status of HNSCC tumours (P ¼ 0.16; Figure 2 ).
DISCUSSION
We have shown that HOP expression is strikingly decreased in hypopharyngeal HNSSC, in 44 out of 46 patients analysed. We also observed decreased HOP expression in tumours by microarray analysis (Cromer et al, 2004) . HOP was found to be expressed in the suprabasal layer of the epithelium, pointing to a role in keratinocyte differentiation.
There is a striking recent convergence of results from several laboratories that indicate that HOP is an important new tumour suppressor. Several studies showed that HOP (mOB1) is expressed during mouse development (Adu et al, 2002) and is involved in cardiac development (Chen et al, 2002; Shin et al, 2002) . More recently, HOP was shown to be a choriocarcinoma suppressor gene involved in cytotrophoblast differentiation (Asanoma et al, 2003) , and to be underexpressed in primary lung tumours compared with normal lung (Chen et al, 2003) . Homeodomain-only protein is located in a chromosomal region (4q11 -q12) that is frequently deleted in solid tumours, including lung tumours, hepatocellular carcinoma and bladder cancer (Petersen et al, 1997; Koo et al, 1999; Sakakura et al, 1999; Wong et al, 1999) . Our study provides evidence for a role of HOP in HNSCC.
HOP consists of 73 amino acids with an unusual 60 amino-acid homeodomain, and is the smallest homeodomain protein to date. Homeodomain proteins are important for embryogenesis and development (reviewed in (Chi and Epstein, 2002; Duboule, 1994) ). HOP does not possess conserved homeodomain residues needed for DNA binding, but modulates cardiac genes expression by direct interaction with SRF and inhibition of SRF binding to DNA (Chen et al, 2002; Shin et al, 2002) .
HOP is widely expressed in mouse and human tissues, suggesting that it may have an important role in many cell types. Using adult human tissue dot blots (Clontech ref PT3307-1), we found expression in oesophagus, lung, placenta, thyroid gland, foetal lung and brain (in decreasing order, data not shown). The cellular localisation of HOP is predicted to be mainly nuclear. We found, by immunocytochemistry with our specific antibodies and HaCat spontaneously immortalized keratinocytes, that endogenous HOP is nuclear (data not shown), in agreement with others (Chen et al, 2002; Shin et al, 2002) .
HOP expression has been detected in primary cultures of normal lung but not in lung tumour-derived cell lines (Chen et al, 2003) . Similarly, we detected, by semiquantitative RT -PCR, expression in primary keratinocytes and HaCat cells, but not in a panel of 15 HNSCC-derived cell lines (data not shown). Reintroduction of HOP in choriocarcinoma cell lines inhibits cell proliferation and tumour formation in nude mice (Asanoma et al, 2003) . We report that HOP expression is decreased in HNSCC tumours compared to their normal matched samples, consistent with studies in other cancer types (Asanoma et al, 2003; Chen et al, 2003) . The reduction of HOP/LAGY expression in lung squamous cell carcinoma is correlated with increasing TNM staging. A complete loss of expression of HOP in two poorly differentiated lung tumour samples has also been reported (Chen et al, 2003) . In our study, there is no statistically significant association with tumour differentiation, suggesting that loss of HOP expression is important in all tumours despite the degree of differentiation. We have shown that HOP is expressed in the suprabasal layer of the upper aerodigestive tract epithelium, suggesting that it is involved in keratinocyte differentiation. HOP is potentially responsible for the balance between proliferation and differentiation of cardiomyocytes in developing heart (Shin et al, 2002) . Overexpression Of HOP in choriocarcinoma cell lines induces the expression of CSH1, a marker of differentiated syncytiotrophoblasts (Asanoma et al, 2003) . Taken together, the results in HNSCC and in other cancer types indicate that HOP could be an important tumour suppressor gene in a wide range of solid tumours.
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